Pfizer registers Q4FY21net profit at Rs 100 Cr
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
The company plans to enter the EU markets in FY22
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
The product patent has been already filed under fast track approval
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Subscribe To Our Newsletter & Stay Updated